Antibody
APP, N-terminal
Quick Links
Clonality: polyclonal
Host: Rabbit
Source: Lab Vision Thermo Scientific
cat# RB9023
References:
Nikolev, 2009
Tampellini, 2007
Formulation: liquid, PBS, BSA, azide, affinity purified; or prediluted, ready to use
Reactivity:
Reacts in: Human, Mouse, Rat
others not tested
Immunogen/Epitope
immunogen = synthetic peptide corr. to N terminal of human APP
Specificity
β-APP770 (110 kDa); predicted to recognize β-APP695 and β-APP771
References
Paper Citations
- Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009 Feb 19;457(7232):981-9. PubMed. RETRACTED
- Tampellini D, Magrané J, Takahashi RH, Li F, Lin MT, Almeida CG, Gouras GK. Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J Biol Chem. 2007 Jun 29;282(26):18895-906. PubMed.
Further Reading
News
- Study Looks to Lithium for Treating ALS—Patients Follow Suit
- Lactam Antibiotics Can Prevent Glutamate Neurotoxicity
- Viral VEGF Treats Mouse ALS
- Microglia in ALS: Helpful, Harmful, or Neutral?
- Motoneuron Mitochondria: Preferred Destination For Mutant SOD1
- Peripheral Innate Immunity—Not So Peripheral to ALS?
- Activated Protein C Battles ALS on Multiple Fronts
- Québec: Transporters, Antibodies Offer Potential ALS Therapies
- Neural Stem Cells and ALS: Delivering the Gift of Growth Factors
- Seeking a Reliable Yardstick for ALS Trials
- News Brief: What’s Up With Iplex?
- IGF-1 Disappoints in Trials for AD, ALS
- Baby Steps Toward Cell Therapies for ALS
- Vocation for VEGF-B—Safely Protect Motor Neurons
- Lithium Takes Indirect Route to Inhibit GSK-3β
- Québec: Stem Cells in ALS Update
Comments / Questions
No Available Comments
Make a comment or submit a question
To make a comment you must login or register.